Here is how MEDVi performs for specific situations
These studies are best interpreted as mechanism-focused evidence rather than complete biological characterization
In SUSTAIN-7, a study comparing semaglutide to dulaglutide in patients with inadequately controlled T2DM, a greater reduction in body weight was observed with 0.5 mg semaglutide (4.6 kg, standard error [SE] 0.28) compared with 0.75 mg dulaglutide (2.3 kg, SE 0.27) (estimated treatment difference [ETD] 2.26 kg, 95% CI 3.02 to 1.51
Semaglutide has been on the market for over a decade for diabetes, and SELECT outcomes data extends past five years
Better Metabolic Health Even at lower doses, GLP-1 can positively impact metabolic health by improving insulin sensitivity, reducing liver fat, and regulating appetite
Here is why maintaining coverage for GLP-1 obesity treatment is the right thing to do: Successfully treating obesity improves peoples lives